# EDGAR Filing Document

**Accession Number:** 0001728328
**File Stem:** 0001213900-25-090695
**Filing Date:** 2025-9
**Character Count:** 6548
**Document Hash:** caf1a4acd86091e1192d8e469b315e37
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-090695.hdr.sgml**: 20250923

**ACCESSION NUMBER**: 0001213900-25-090695

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250923

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250923

**DATE AS OF CHANGE**: 20250923

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** InMed Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001728328
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39685
- **FILM NUMBER:** 251334516

**BUSINESS ADDRESS:**
- **STREET 1:** 1445-885 WEST GEORGIA ST.
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 3E8
- **BUSINESS PHONE:** (604) 669-7207

**MAIL ADDRESS:**
- **STREET 1:** 1445-885 WEST GEORGIA ST.
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6C 3E8

?xml version='1.0' encoding='ASCII'?

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**FORM 8-K**

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported): September 23, 2025**

**INMED PHARMACEUTICALS INC.** 

**(Exact Name of Company as Specified in Charter)** 

---

| | | |
|:---|:---|:---|
| **British Columbia** | **001-39685** | **98-1428279** |
| **(State or Other Jurisdiction <br> of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br> Identification No.)** |

---

---

| | |
|:---|:---|
| **InMed Pharmaceuticals Inc.<br> Suite 1445 - 885 W. Georgia Street,<br> Vancouver, B.C. <br> Canada** | **V6C 3E8** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Company's telephone number, including area code: (604) 669-7207**

**Not applicable** 

**(Former Name or Former Address, if Changed Since Last Report)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Shares, no par value** | **INM** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 8.01 Other Events**

On September 23, 2025, InMed Pharmaceuticals Inc. announced the meeting, record date and certain other information relating to its 2025 annual meeting of shareholders pursuant to a filing submitted to the System for Electronic Document Analysis and Retrieval ("SEDAR") in Canada.

The information set forth in this Item 7.01, including Exhibits 99.1 and 99.2, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01.** **Financial Statements and Exhibits.** 

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [SEDAR filing submitted September 23, 2025](ea025852301ex99-1_inmed.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) |

---

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | INMED PHARMACEUTICALS INC. | INMED PHARMACEUTICALS INC. |
| Date: September 23, 2025 | By: | /s/ Eric A. Adams |
|  |  | Eric A. Adams |
|  |  | President and CEO |

---

## Exhibit 99.1

**Exhibit 99.1**

---

| | |
|:---|:---|
| September 23, 2025 | ![](ex99-1_001.jpg) |

---

*Filed via SEDAR+*

 

To All Applicable Exchanges and Securities Administrators

---

| | |
|:---|:---|
| **Subject:** | **InMed Pharmaceuticals Inc. (the "Issuer")** |
|  | **Notice of Meeting and Record Date** |

---

Dear Sir/Madam:

We are pleased to confirm the following information with respect to the Issuer's upcoming meeting of securityholders:

---

| | |
|:---|:---|
| Meeting Type: | Annual General Meeting |
| Meeting Date: | December 17, 2025 |
| Record Date for Notice of Meeting: | October 22, 2025 |
| Record Date for Voting (if applicable): | October 22, 2025 |
| Beneficial Ownership Determination Date: | October 22, 2025 |
| Class of Securities Entitled to Vote: | Common Shares |
| ISIN: | CA4576377002 |
| Issuer sending proxy materials directly to NOBOs: | No |
| Issuer paying for delivery to OBOs: | No |
| Notice and Access for Beneficial Holders: | Yes |
| Notice and Access for Registered Holders: | Yes |

---

In accordance with applicable securities regulations we are filing this information with you in our capacity as agent of the Issuer.

Yours truly,

---

| |
|:---|
| **Odyssey Trust Company** |
| **as agent for InMed Pharmaceuticals Inc.** |

---